2 recovering growth stocks to help you achieve financial independence

These two bombed-out growth stocks could be set for a storming comeback.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Shares in Quantum Pharma (LSE: QP) had already been falling when a shock profit warning at first-half results time in October saw a further 50% knocked off the price.

Incoming chief executive Chris Rigg had launched a major operational review, and a trading update Wednesday showed just how far the company has come — impressing the markets enough for a 6% share price rise to 58.5p on the day.

Non-core activities have been dumped as the firm has been refocusing on its Niche Pharmaceuticals business, which is now described as “a highly profitable division” with an improving development pipeline.

With plans to expand internationally, Quantum is apparently ahead of its strategic plan — and that plan has already resulted in an improved financial performance and higher overall margins.

Net debt was slashed in half by the time the full year was reported in May, thanks to a £15m placing, and the lossmaking NuPharm being closed, though the company did report a pre-tax loss of £10.9m.

From the ruins

In short, the new Quantum Pharmaceuticals looks like a very different entity to its first incarnation from its original flotation in 2014, but I don’t think the markets have yet woken up to the potential of the regenerated company.

Forecasts indicate a return to profit for the year to January 2018, with earnings growth of 32% pencilled in for the following year, sending the P/E down as low as 14 and giving us a PEG of just 0.45. To me, that’s a very attractive valuation for a company with these growth prospects.

Those who bought in the dip after last year’s price crash will have seen their investment rise by close to 70% by now, but I reckon there’s still time to grab a bargain.

A Neil Woodford bargain?

In biotechnology probably more than anywhere, early promises often fail and the risks come home to roost. That much is clear from Circassia Pharmaceuticals (LSE: CIR), a growth prospect that top investor Neil Woodford bought a chunk of.

But the firm’s big promise, a cat allergy vaccine, failed in its phase III trials. That was followed by a dust mite allergy study failing to meet its phase IIb primary endpoint in April this year, bringing to an end the company’s investment in allergy research.

Since the bad news hit, Circassia shares have lost two-thirds of their value, as early growth investors fled. But Neil Woodford didn’t sell, seeing value in what was left of the firm at its new low price — and there’s actually still quite a lot left.

Impressive portfolio

The firm has a range of successful respiratory treatments, and has signed up with AstraZeneca to commercialise two of its COPD products in the US — and its US sales force is ramping up as a result.

Sales of asthma management product NIOX are growing too, up to £23m in 2016, and chief executive Steve Harris reckoned Circassia is heading to become a “world-class, self-sustaining specialty pharmaceutical business.

All of this promise will count for nought if we never see any profits, and there are none on the analysts’ radar for this year or next. But Mr Woodford has said that he sees the firm as being “very well-financed” and thinks he sees “long-term value in the shares.

For me that cements Circassia as a buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

How much passive income could a £20,000 ISA provide in a year?

A diversified portfolio of high-yield FTSE shares can build a large and reliable passive income over time, as Royston Wild…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

See how much an investor needs in an ISA to fund an £888 monthly passive income

Harvey Jones grabs his calculator to work out how much money people need to generate a decent passive income in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Value Shares

The BP share price is climbing – see how much £10k invested 1 month ago is worth now

It's been a tough few years for the BP share price. Harvey Jones examines whether the FTSE 100 oil giant…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock has soared 1,471% in 5 years. Here’s how I’m hunting for the next Nvidia!

Nvidia stock has put in a stunning performance over the past five years. This writer tries to apply some lessons…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

If someone decided to start buying shares with £10k a year ago, here’s what they could be sitting on now!

If someone had started buying shares a year ago with £10k, what might have happened? Our writer outlines some factors…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

The Rolls-Royce share price is close to an all-time record. Could it still be a bargain?

The Rolls-Royce share price has been punching out the lights of late. Our writer thinks things could get even better…

Read more »

4 Teslas in a parking lot at a charger station
Investing Articles

The Tesla share price slips further — how much would £10k invested at the start of the year be worth now?

The Tesla share price remains under pressure, with risks mounting from multiple directions. Here’s what a £10,000 investment would be…

Read more »

British pound data
Investing Articles

The Ocado share price is a sea of red! Time to cut my losses?

Every time Harvey Jones checks out the Ocado share price, he sees red. Will it ever stop falling and leaving…

Read more »